Cancer clinical trials in the region Île-de-France
697 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Lymphoma
CLL & Richter's syndrome
Acute leukemia
#NCT04707300
#2019-004883-23
Required histologic types
CLL (Chronic Lymphocytic Leukemia)
Acute lymphoblastic leukemia (ALL)
Acute myeloid leukemia (AML)
4 recruiting sites
Assistance Publique - Hôpitaux de Paris
Phase 1 / Phase 2
Acute leukemia
#NCT04150497
Required histologic types
Acute lymphoblastic leukemia (ALL)
Required histologic sub types
B-cell (B-ALL)
Required number of previous lines of therapy
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
Cellectis SA
Phase 1 / Phase 2
Prostate cancer
#NCT06907043
#2024-520395-99-00
Cohorte cancer de la prostate résistant à la castration
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required genetic anomalies
ATM
BRCA 1/2
CHEK 1/2
Other mutation
PALB2
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Chemotherapy
Hormone therapy
2 recruiting sites
Eikon Therapeutics
Phase 1 / Phase 2
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT06907043
#2024-520395-99-00
Cohorte cancer de l'ovaire
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Endometrioid carcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
BRCA 1/2
ATM
Other mutation
CHEK 1/2
PALB2
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Eikon Therapeutics
Phase 1 / Phase 2
Breast cancer
#NCT06907043
#2024-520395-99-00
Cohorte Cancer du sein
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
BRCA 1/2
PALB2
ATM
Other mutation
CHEK 1/2
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Chemotherapy
2 recruiting sites
Eikon Therapeutics
Phase 1 / Phase 2
Pancreas cancer
#NCT06907043
#2024-520395-99-00
Cohorte cancer du pancréas
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
BRCA 1/2
PALB2
ATM
Other mutation
CHEK 1/2
Required number of previous lines of therapy for current stage of disease
1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Eikon Therapeutics
Phase 1 / Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT06818643
#2024-516817-19-00
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Merck Sharp & Dohme LLC
Phase 1 / Phase 2
Prostate cancer
#NCT07258407
#2025-523273-41-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required PSMA PET Scan statuses
PSMA PET Positive
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
T.O.A.D. Oncology SA
Phase 1 / Phase 2
Lung cancer
Prostate cancer
Stomach and esophageal cancer
#NCT05434234
Required histologic types
SCLC (Small Cell Lung Cancer)
NSCLC (Non-Small Cell Lung Cancer)
Esophagus
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1 / Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT06697197
#2024-516602-28-00
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Bristol-Myers Squibb